Assetmark, Inc Bio N Tech Se Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in Bio N Tech Se stock. As of the latest transaction made, Assetmark, Inc holds 20 shares of BNTX stock, worth $2,261. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 20 -0.0%

Holding current value

$2,261

Previous $1,000 100.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$88.96 - $112.35 $2,490 - $3,145	-28 Reduced 58.33%	20 $1,000
Q4 2023 Feb 09, 2024	SELL	$90.91 - $112.75 $179,638 - $222,794	-1,976 Reduced 97.63%	48 $5,000
Q3 2023 Oct 27, 2023	SELL	$98.5 - $125.08 $5,417 - $6,879	-55 Reduced 2.65%	2,024 $219,000
Q2 2023 Aug 11, 2023	BUY	$102.58 - $129.66 $31,697 - $40,064	309 Added 17.46%	2,079 $224,000
Q1 2023 May 05, 2023	BUY	$122.57 - $153.67 $51,847 - $65,002	423 Added 31.4%	1,770 $220,000
Q4 2022 Feb 10, 2023	BUY	$118.43 - $186.05 $8,763 - $13,767	74 Added 5.81%	1,347 $202,000
Q3 2022 Nov 01, 2022	SELL	$127.65 - $183.11 $4,850 - $6,958	-38 Reduced 2.9%	1,273 $172,000
Q2 2022 Aug 03, 2022	BUY	$123.25 - $186.24 $4,930 - $7,449	40 Added 3.15%	1,311 $195,000
Q1 2022 May 13, 2022	SELL	$126.25 - $231.85 $29,416 - $54,021	-233 Reduced 15.49%	1,271 $217,000
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $309,795 - $518,403	1,430 Added 1932.43%	1,504 $388,000
Q3 2021 Nov 12, 2021	BUY	$205.93 - $447.23 $15,238 - $33,095	74 New	74 $20,000

Others Institutions Holding BNTX

# of Institutions

357

Shares Held

38.3M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.4B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account